For weeks, more than half a million Anthem Blue Cross enrollees who receive health care from the University of California were held in suspense.
Ideaya showcases proof-of-concept data in a boost to synthetic lethality play
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS